From manual flask‑based culture to GMP bioreactor expansion: automation strategies and data for adherent cell manufacturing

Early automation decisions in adherent cell therapy manufacturing carry lasting consequences for cost, scalability, regulatory acceptance, and speed to clinic. Here, Mandana Haack‑Sørensen (Director of Manufacturing, Cell to Cure) and Nathan Frank (Senior Research Scientist, Terumo Blood and Cell Technologies) discuss the lessons learned from one organization’s journey from manual, flask‑based production to fully automated, GMP‑compliant bioreactor manufacturing, and data from hollow‑fiber bioreactor expansion of several adherent cell types, including HEK‑293T cells, induced pluripotent stem cells (iPSCs), and bone marrow‑derived mesenchymal stem cells (MSCs).

What you will learn

01

Why manual flask-based culture limited dose consistency, scale, and cost in autologous MSC trials

02

How a closed bioreactor transition enabled allogeneic manufacturing across 13 trials and 300+ patients

03

What hollow-fiber expansion data show for HEK-293T cells, iPSCs, and whole bone marrow MSCs

Key interests

Adherent cell manufacturing Hollow-fiber bioreactor Process automation Allogeneic MSCs iPSC expansion HEK-293T cells GMP comparability Commercialization

Please enter your email to access content Read now